PharmaShots | Incisive News in 3 Shots

Subscribe Now

MindMed

MindMed Receives US Patent for MM120 to Treat Generalized Anxiety Disorder

MindMed Receives US Patent for MM120 to Treat Generalized Anxiety Disorder

July 17, 2024

MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (GAD)

MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (...

March 8, 2024

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

August 29, 2023

MindMed Entered into an Exclusive License Agreement with Catalent for Patented Zydis Fast-Dissolve Technology Incorporated in MM-120

MindMed Entered into an Exclusive License Agreement with Catalent for Patented Zydis Fast-Dissolve Technology Incorporated in MM-1...

August 3, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us